20
September

11:00 AM EST

Accelerate Drug Discovery

with AI-driven Drug Design Virtual Boardroom

What to expect

Timely information, interactive format

Expiring patents and unmet patient needs demand faster and better innovation in Drug Discovery. An impactful method is to augment physical research experimentation with Artificial Intelligence (AI) and Machine Learning (ML) in drug design. Leveraging internal and external scientific data for active learning allows organizations to focus on the most promising targets and reduce time-consuming and expensive physical testing. In this round table we will discuss how “bridging the gap between the virtual and the real” will impact drug discovery in the future. Join us to discuss how science and technology can advance discovery by using the virtual twin to accelerate drug design.

Online Agenda

Why you should attend

We invite you to contribute your expertise to an exclusive boardroom discussion about AI-driven Drug Discovery. Join us to discuss how science and technology can advance discovery by using the virtual twin to accelerate drug design.

Meet the Facilitator

The virtual boardroom will be lead by our expert facilitator

Jason Benedict

BIOVIA CEO & Vice President R&D Dassault Systèmes

More about BIOVIA, Dassault Systèmes

More information

BIOVIA, a brand of Dassault Systèmes, provides a scientific collaborative environment for advanced biological, chemical and materials experiences that allows science-driven companies access, organize, analyze and share data in unprecedented ways throughout the product lifecycle in regulated and non-regulated environments. BIOVIA’s sophisticated enterprise portfolio of Scientific Informatics, Molecular Modeling & Simulation, Data Science, Laboratory Informatics, Formulation Design, Life Sciences Quality & Compliance and Manufacturing Analytics helps drive innovation, increase productivity, improve quality and compliance, reduce costs and accelerate time to market. BIOVIA is committed to enhancing and speeding innovation, increasing productivity, improving quality and compliance, reducing costs and accelerating product development for pharma and biotech companies around the world.”

Further Information

Interested in attending this virtual roundtable or running your own? Drop us a message today and we will get in touch.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Biovia US

BIOVIA Virtual Boardroom – 20th September 2022

Accelerate Drug Discovery

with AI-driven Drug Design Virtual Boardroom

Timely information, interactive format

Online Agenda

Sharing experiences of leveraging AI and ML to accelerate drug design.

Understanding how AI/ML can be combined with physical experiments to improve your current approach to drug design

Discuss the benefits, hurdles and expectations of virtually augmented drug design

Why you should attend

Meet the Facilitator

Jason Benedict

More about BIOVIA, Dassault Systèmes

Further Information

Select days you wish to attend You can add multiple days

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Rheumatology

Endocrinology

Nephrology

Surgery

ENT

Neurology

Urology

Gastroenterology

Oncology

Vaccines

Haematology

Ophthalmology

Thrombosis

Rare Diseases

This is required field*

0-10

10-50

50-100

100-500

500+

This is required field*

This is required field*

Under £100,000

£100,000 - £500,000

£500,000 - £1,000,000

£1,000,000 - £5,000,000

£5,000,000 - £10,000,000

£10,000,000 +

This is required field*

This is required field*

Discovery to Development

Pre-Clinical

Phase 1

Phase 2

Phase 3

Phase 4

This is required field*